Risk factors in multiple myeloma: is it time for a revision?
Risk factors in multiple myeloma: is it time for a revision?
复制标题
DOI：
10.1182/blood.2019004309
复制
发表时间：
2021-01-07
期刊：
影响因子：
20.3
通讯作者：
Avet-Loiseau, Herve
中科院分区：
文献类型：
--
作者：
Corre, Jill;Munshi, Nikhil C.;Avet-Loiseau, Herve
虽然治疗策略已适应年龄和合并症很长一段时间，几乎所有的多发性骨髓瘤（MM）患者目前接受类似的治疗，无论其疾病风险类别。然而，高风险MM患者仍然构成未满足的医疗需求，应该从最有效的药物组合中获益。在此，我们回顾和讨论如何最佳地定义风险，以及为什么迫切需要修改当前的定义。
Although therapeutic strategies have been adapted to age and comorbidities for a long time, almost all multiple myeloma (MM) patients currently receive similar treatment, whatever their disease risk category. However, high-risk MM patients still constitute an unmet medical need and should benefit from the most efficient drug combinations. Herein, we review and discuss how to optimally define risk and why a revision of the current definition is urgently needed.